Joachim Boos Selected Research

Asparaginase (Elspar)

1/2022	Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.
1/2020	Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia.
1/2020	Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study.
4/2019	Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002.
1/2019	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.
12/2017	Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia.
11/2014	The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
2/2013	No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
3/2012	Population pharmacokinetics of native Escherichia coli asparaginase.
11/2011	Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joachim Boos Research Topics

Disease

25	Neoplasms (Cancer) 01/2021 - 01/2005
17	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 02/2002
6	Neuroblastoma 07/2011 - 09/2004
5	Hypersensitivity (Allergy) 03/2022 - 01/2011
5	Ewing Sarcoma (Sarcoma, Ewing) 07/2018 - 10/2003
4	Body Weight (Weight, Body) 07/2014 - 03/2010
4	Osteosarcoma (Osteogenic Sarcoma) 07/2011 - 02/2005
3	Sarcoma (Soft Tissue Sarcoma) 01/2012 - 04/2008
2	Cardiotoxicity 01/2020 - 12/2016
2	Leukemia 03/2010 - 07/2006
1	Cardiomyopathies (Cardiomyopathy) 10/2020
1	Ototoxicity 01/2015
1	Disease Progression 11/2014
1	Hypercholesterolemia 11/2014
1	Pancreatitis 11/2014
1	Thrombosis (Thrombus) 11/2014
1	Hypertriglyceridemia 11/2014
1	Hyperammonemia 11/2014
1	Dyslipidemias (Dyslipidemia) 11/2014
1	Flushing 06/2014
1	Aspergillosis 04/2013
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 06/2012
1	Alveolar Rhabdomyosarcoma 01/2012
1	Residual Neoplasm 09/2011
1	Carcinogenesis 06/2010
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 05/2008
1	Rare Diseases (Rare Disease) 02/2007
1	Renal Insufficiency (Renal Failure) 04/2005

Drug/Important Bio-Agent (IBA)

14	Asparaginase (Elspar)FDA Link 01/2022 - 10/2002
9	Pharmaceutical PreparationsIBA 01/2020 - 08/2006
6	pegaspargase (Oncaspar)FDA Link 03/2022 - 09/2002
6	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2020 - 02/2002
4	Etoposide (VP 16)FDA LinkGeneric 07/2018 - 09/2005
4	Busulfan (Busulfex)FDA Link 07/2014 - 03/2005
3	AntibodiesIBA 03/2022 - 01/2011
3	AsparagineIBA 01/2019 - 10/2002
2	Vincristine (Oncovin)FDA LinkGeneric 06/2015 - 12/2002
2	EnzymesIBA 11/2011 - 10/2002
2	Gemcitabine FDA Link 01/2011 - 08/2006
2	Methotrexate (Mexate)FDA LinkGeneric 08/2010 - 04/2005
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2006 - 09/2005
2	Diphosphonates (Bisphosphonates)IBA 09/2004 - 10/2003
2	Clodronic Acid (Clodronate)IBA 09/2004 - 10/2003
2	Pamidronate (Aredia)FDA LinkGeneric 09/2004 - 10/2003
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 03/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Cytostatic AgentsIBA 10/2020
1	NucleotidesIBA 01/2020
1	benzyloxycarbonylleucyl-leucyl-leucine aldehydeIBA 07/2018
1	Topoisomerase II InhibitorsIBA 07/2018
1	Proteasome Endopeptidase Complex (Proteasome)IBA 07/2018
1	Proteasome InhibitorsIBA 07/2018
1	Topotecan (Hycamtin)FDA LinkGeneric 07/2018
1	Topoisomerase I InhibitorsIBA 07/2018
1	Natriuretic PeptidesIBA 12/2016
1	TroponinIBA 12/2016
1	Messenger RNA (mRNA)IBA 03/2016
1	LigandsIBA 03/2016
1	Cisplatin (Platino)FDA LinkGeneric 01/2015
1	Triglycerides (Triacylglycerol)IBA 11/2014
1	Caspofungin (Cancidas)FDA Link 04/2013
1	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2012
1	CreatinineIBA 01/2012
1	trofosfamideIBA 01/2012
1	BilirubinIBA 01/2012
1	ElementsIBA 09/2011
1	SteroidsIBA 09/2011
1	Methylnitronitrosoguanidine (MNNG)IBA 07/2011
1	Phosphotransferases (Kinase)IBA 07/2011
1	5- (5,6- dimethoxy- 1H- benzimidazol- 1- yl)- 3- ((2- (trifluoromethyl)benzyl)oxy)thiophene- 2- carboxamideIBA 07/2011
1	Glucose (Dextrose)FDA LinkGeneric 03/2011
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2011
1	daunorubicinolIBA 03/2010
1	Daunorubicin (Cerubidine)FDA LinkGeneric 03/2010
1	Tumor Suppressor Protein p14ARF (p14ARF)IBA 02/2010
1	ukrainIBA 10/2006
1	AlkaloidsIBA 10/2006
1	BromidesIBA 07/2006
1	treosulfanIBA 07/2006
1	Carboplatin (JM8)FDA LinkGeneric 09/2005
1	Melphalan (Alkeran)FDA LinkGeneric 09/2005
1	gamma-Glutamyl Hydrolase (Carboxypeptidase G2)IBA 04/2005
1	Acetaminophen (Paracetamol)FDA LinkGeneric 02/2005
1	Platinum Compounds (Compounds, Platinum)IBA 01/2005

Therapy/Procedure

12	Therapeutics 04/2019 - 10/2003
5	Drug Therapy (Chemotherapy) 01/2012 - 02/2005
3	Aftercare (After-Treatment) 01/2021 - 10/2015
2	Radiotherapy 01/2020 - 07/2003
2	Remission Induction 01/2011 - 10/2002
2	Investigational Therapies (Experimental Therapy) 01/2011 - 06/2010
1	Fitness Trackers 01/2018
1	Withholding Treatment 06/2015
1	Hematopoietic Stem Cell Transplantation 06/2012
1	Salvage Therapy 01/2011
1	Neoadjuvant Therapy 12/2010
1	Drug Tapering 03/2010
1	Cranial Irradiation 05/2008
1	Stem Cell Transplantation 09/2005
1	Maintenance Chemotherapy 09/2005
1	Analgesia 02/2005